Clinical Trial Update: LMY-920 for Treatment of Relapsed or Refractory Myeloma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for LMY-920 in relapsed or refractory multiple myeloma; recruitment is ongoing by Luminary Therapeutics.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• LMY-920

Snippet

Sponsor: Luminary Therapeutics | Conditions: Multiple Myeloma, Refractory, Multiple Myeloma in Relapse | Phase 1 | Status: RECRUITING